Ardelyx Inc (ARDX) Stock Price, Quote & News

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 745 1700

Website: www.ardelyx.com

Address:

400 Fifth Avenue, Suite 210, Waltham, United States

UKbiotechInsider Sep. 13 at 6:48 PM

$ARDX long ride to 2029..

0 · Reply

donkeykongreturns Sep. 13 at 5:12 PM

$ARDX Some more of my convos with AI on where "Multiple Therapies" could be going as a CKM patient focused solution that most directly impacts gov payers - 2 parts

2 · Reply

opportoni Sep. 13 at 1:51 PM

$ARDX Looking at the recent developments in the middle east, I am quite sure the market will tank tomorrow already, but surely the stable genius has it all baked into his plan of winning so much that we will all beg him to stop.

2 · Reply

opportoni Sep. 13 at 7:52 AM

$ARDX The good news is: We are almost through Q3. We may get good vibes from the committee meeting this week, but to really turn this ship around we need a good Q3. Prescriptions seem to be ok. Maybe some catchup from what was delayed in Q2. Cost increase should be slowing down from what Sue told us and, importantly, valuation is way too low already.

1 · Reply

benji1298 Sep. 12 at 11:57 PM

$ARDX does anyone have access to the most recent analyst reports for any of the main analysts covering this? Would appreciate being able to read the full reports vs just getting the targets. Thanks

1 · Reply

RigidFlexibility Sep. 12 at 7:23 PM

$ARDX …buy Now. Hold. Reap later. Classic plan. Bully. Bully. Yeah, I’m under. But optimistic. GLTA

0 · Reply

plavac Sep. 12 at 6:31 PM

$ARDX

0 · Reply

MrMoneyBags4 Sep. 12 at 5:53 PM

$ARDX I just try to forget I own this stock… makes my life easier.

0 · Reply

donkeykongreturns Sep. 12 at 4:03 PM

$ARDX The new molecule's application in cardiorenal is where investors should be focused. The pharma industry is always on the lookout for heart <> kidney health. https://www.biopharmadive.com/news/novartis-ionis-pelacarsen-lpa-horizon-study-results-fail/829736/?utm_source=Sailthru&utm_medium=email&utm_campaign=Newsletter%20Weekly%20Roundup:%20BioPharma%20Dive:%20Daily%20Dive%2009-12-2026&utm_term=BioPharma%20Dive%20Weekender

2 · Reply

findingthestock Sep. 12 at 3:52 PM

$ARDX Stock is going down because a buyout is right around the corner makes no sense. Mott hasn’t bought since Feb doesn’t mean there’s a buyout happening. We don’t know the reasons why Mott hasn’t bought though it’s concerning after consistently buying. These conferences aren’t doing anything for stock price as we can see Therefore with no other catalysts what is going to change. Worried the stock can continue to crater with also overall market conditions XBI going down bio sector Can this be heading to twos. This has become a very risky investment

2 · Reply

Ardelyx Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 1, 2026, 7:30 AM EDT - 12 days ago

Ardelyx to Participate in Upcoming Investor Conferences

2026-08-17T11:07:10.000Z - 27 days ago

Ardelyx price target lowered to $15 from $16 at Piper Sandler

Aug 14, 2026, 10:07 AM EDT - 4 weeks ago

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

2026-08-10T10:50:33.000Z - 4 weeks ago

Ardelyx price target lowered to $11 from $14 at Citi

2026-08-07T13:36:54.000Z - 5 weeks ago

Ardelyx price target lowered to $15 from $19 at Raymond James

2026-08-07T13:22:10.000Z - 5 weeks ago

Ardelyx price target lowered to $10 from $13 at TD Cowen

2026-08-07T10:16:42.000Z - 5 weeks ago

Ardelyx price target lowered to $13 from $16 at H.C. Wainwright

2026-08-06T20:56:38.000Z - 5 weeks ago

Ardelyx reports Q2 EPS (7c), consensus (5c)

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Ardelyx Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Ardelyx Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Ardelyx Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 5 weeks ago

Ardelyx Slides: Q2 2026

Jul 23, 2026, 8:01 AM EDT - 7 weeks ago

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

2026-06-26T19:20:10.000Z - 2 months ago

Jefferies says Ardelyx CMS appeal loss ‘shouldn’t fundamentally change anything’

2026-06-16T11:57:58.000Z - 2 months ago

Ardelyx assumed with a Buy at Ladenburg

Jun 3, 2026, 9:55 AM EDT - 3 months ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 8:00 AM EDT - 3 months ago

Ardelyx Proxy statement: Proxy filing

May 19, 2026, 8:01 AM EDT - 3 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

May 19, 2026, 8:00 AM EDT - 3 months ago

Ardelyx Proxy statement: Proxy filing

May 7, 2026, 8:01 AM EDT - 4 months ago

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

2026-04-30T21:07:15.000Z - 4 months ago

Ardelyx reports Q1 EPS (15c), consensus (14c)

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Ardelyx Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Ardelyx Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Ardelyx Quarterly report: Q1 2026

Apr 30, 2026, 4:01 PM EDT - 4 months ago

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Ardelyx Proxy statement: Proxy filing

Apr 27, 2026, 8:01 AM EDT - 4 months ago

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Apr 23, 2026, 8:01 AM EDT - 4 months ago

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

2026-04-22T11:54:28.000Z - 4 months ago

Jade Biosciences appoints Edward Conner as chief medical officer

JBIO

2026-04-20T12:50:41.000Z - 4 months ago

Ardelyx appoints Ettenberg as Chief Legal Officer

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

BMY

Apr 16, 2026, 8:01 AM EDT - 5 months ago

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

2026-04-01T12:17:42.000Z - 5 months ago

Ardelyx appoints Rajani Dinavahi as chief medical officer

Apr 1, 2026, 8:01 AM EDT - 5 months ago

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Mar 12, 2026, 8:00 AM EDT - 6 months ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar 10, 2026, 4:20 PM EDT - 6 months ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:05 PM EDT - 6 months ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

2026-03-05T13:09:46.000Z - 6 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ZVRA

2026-02-24T13:18:35.000Z - 6 months ago

Ardelyx, LPGA announce multi-year partnership

Feb 24, 2026, 8:00 AM EST - 6 months ago

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

2026-02-20T11:12:08.000Z - 6 months ago

Ardelyx price target raised to $18 from $10 at H.C. Wainwright

2026-02-19T22:00:37.000Z - 6 months ago

Ardelyx reports Q4 EPS 0c, consensus 1c

Feb 19, 2026, 4:30 PM EST - 6 months ago

Ardelyx Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 6 months ago

Ardelyx Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 6 months ago

Ardelyx Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 6 months ago

Ardelyx Slides: Q4 2025

Feb 19, 2026, 4:01 PM EST - 6 months ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 5, 2026, 8:00 AM EST - 7 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Feb 3, 2026, 8:29 AM EST - 7 months ago

Ardelyx Receives New Patent for Tenapanor

Jan 28, 2026, 8:29 AM EST - 7 months ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

Jan 8, 2026, 8:30 AM EST - 8 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Nov 19, 2025, 11:30 AM EST - 9 months ago

Ardelyx Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 11:30 AM EST - 10 months ago

Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference

Nov 7, 2025, 4:05 PM EST - 10 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 5, 2025, 8:00 AM EST - 10 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Oct 30, 2025, 4:30 PM EDT - 10 months ago

Ardelyx Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

Ardelyx Quarterly report: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 10 months ago

Ardelyx Earnings release: Q3 2025

Oct 30, 2025, 4:01 PM EDT - 10 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:01 AM EDT - 10 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 13, 2025, 8:35 AM EDT - 11 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:30 AM EDT - 11 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Sep 9, 2025, 11:30 AM EDT - 1 year ago

Ardelyx Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Ardelyx Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 8:35 AM EDT - 1 year ago

Ardelyx Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 1 year ago

Ardelyx Transcript: Citi's Biopharma Back to School Conference

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q2 2025

Aug 4, 2025, 4:08 PM EDT - 1 year ago

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:01 PM EDT - 1 year ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

May 21, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 6, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q1 2025

May 1, 2025, 4:01 PM EDT - 1 year ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Ardelyx Slides: Corporate Presentation

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 24, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

UKbiotechInsider Sep. 13 at 6:48 PM

$ARDX long ride to 2029..

0 · Reply

donkeykongreturns Sep. 13 at 5:12 PM

$ARDX Some more of my convos with AI on where "Multiple Therapies" could be going as a CKM patient focused solution that most directly impacts gov payers - 2 parts

2 · Reply

opportoni Sep. 13 at 1:51 PM

2 · Reply

opportoni Sep. 13 at 7:52 AM

1 · Reply

benji1298 Sep. 12 at 11:57 PM

$ARDX does anyone have access to the most recent analyst reports for any of the main analysts covering this? Would appreciate being able to read the full reports vs just getting the targets. Thanks

1 · Reply

RigidFlexibility Sep. 12 at 7:23 PM

$ARDX …buy Now. Hold. Reap later. Classic plan. Bully. Bully. Yeah, I’m under. But optimistic. GLTA

0 · Reply

plavac Sep. 12 at 6:31 PM

$ARDX

0 · Reply

MrMoneyBags4 Sep. 12 at 5:53 PM

$ARDX I just try to forget I own this stock… makes my life easier.

0 · Reply

donkeykongreturns Sep. 12 at 4:03 PM

2 · Reply

findingthestock Sep. 12 at 3:52 PM

2 · Reply

Str8balln Sep. 12 at 11:33 AM

$ARDX Seriously… it has to be around the corner!!!! Merger/Buyout Monday!

2 · Reply

Cameohitch Sep. 12 at 9:34 AM

$ARDX "Join us at Fierce Pharma Week! We're proud to have Murali Gopal, M.D., Senior Vice President and Head of Medical Affairs, participating in the panel discussion, "Build Scientific Engagement That Strengthens Trust Across Every Channel." The session will explore how organizations can foster trusted and meaningful connections across today's evolving healthcare landscape." https://www.linkedin.com/posts/ardelyx-inc-_fiercepharmaweek-activity-7504159089086857216-RJIi

1 · Reply

InvestRX2017 Sep. 12 at 5:48 AM

$ARDX Rubric’s estimated cost basis for its 16M share position is around 5.90 (-37% fro current levels - ouch). that is a consolation for me…

3 · Reply

InvestRX2017 Sep. 12 at 4:24 AM

$ARDX anyone else find amusing that today’s market cap of 902M is around the same as Nov 1, 2023 (914MM) when X was just approved. sure, i get it, the company is not profitable yet, but what the f$@&):ck is wrong with the market???

1 · Reply

Stocks2Retire Sep. 11 at 10:36 PM

$ARDX so sad.. the future here depends on either ceo Raab performing and sttaying his lane or WashingtonDC lawmakers doing their duty and passing healthcarebill, in an election year when everything is on the line for them and their parties. Now you know why we are drifting towards 3.00. At this rate, even a brief visit to 2.xx may not be off the cards here 🙂

1 · Reply

Luckydog63 Sep. 11 at 10:27 PM

$ARDX Look at that chart, now that is abusive. $3.50 is just crazy but these cockroaches and termites got Billions and Billions so be careful. Raabs every other month sell of 41,666 due next week and interest rates on Weds. Coupled with another fireside chat with a chimney fire. Thinking of buying more as well but probably waiting a bit longer. The Closing chart today shows you they are in charge...termites and cockroaches.

0 · Reply

Alshati Sep. 11 at 9:04 PM

$ARDX There is clear manipulation by the controlling funds in the stock, and the goal is to scare individual investors. There is no other way to get retail investors' shares except with this method, and if you don't buy and increase your quantity, then when will you buy? I expect — in fact I'm almost certain — that the stock will open with a very large gap in the coming weeks that won't give anyone a chance to catch up with it.

2 · Reply

djgestates Sep. 11 at 8:47 PM

$ARDX

0 · Reply

Bear0927 Sep. 11 at 8:42 PM

$ARDX Wait...so at $3.58 the market is not trusting the growth trajectory on Ibsrela due to payor friction hurdles despite increased demand (can change), it's saying it doesn't like ARDX's debt (could be profitable in 2-3 quarters), it's saying Xphozah has little to no potential for increased uptake and revenue (can change), it ascribes near zero value to rest of world utilization (can change), it gives zero value to the CIC market (it's likely coming), and it's giving me the optionality on RDX10531 and the NHE3 inhibition mechanism as a whole for expanded indications for free. I love it when the market is absurd. Thank you for this opportunity.

1 · Reply

5StarTrader Sep. 11 at 8:31 PM

$ARDX Remember we had the greatest number of bipartisan cosponsors for the bill just last year. It’s fairly certain that once the legislation is put on the floor for a vote, it will pass. And with midterms looming, every single Politician will want to have the bragging rights of this bill being passed so they can be campaigning for the massive kidney patient voting bloc.

3 · Reply

scdorsey22 Sep. 11 at 8:27 PM

$ARDX gross lol. Multi year support in the 3.20’s. Seller of all those Jan $4 put contracts betting that price stabilizes here/there as well so can’t imagine it gets too much worse from here. Think this is the worst sentiment I’ve seen in this stock (wasn’t in it during CRL times) Haven’t added any post ER but might start to nibble soon. Think they will turn it around

2 · Reply

plavac Sep. 11 at 8:27 PM

$ARDX Bull markets are born in despair and die in euphoria. The last cycle (last year) went from $3.30 to $8.40, I think this one with the announced profitability next year can go up to $10.

0 · Reply

Market Cap	902.06M
Revenue (ttm)	407.32M
Net Income (ttm)	-61.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.12%
Debt to Equity Ratio	1.69

Volume	5,690,200
Avg Vol	3,950,918
Day's Range	N/A - N/A
Shares Out	249.19M
Stochastic %K	6%
Beta	0.70
Analysts	Strong Sell
Price Target	$12.90